Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Reata Pharmaceuticals stock | $97.23

Learn how to easily invest in Reata Pharmaceuticals stock.

Reata Pharmaceuticals Inc is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 261 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Reata Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RETA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Reata Pharmaceuticals stock price (NASDAQ: RETA)

Use our graph to track the performance of RETA stocks over time.

Reata Pharmaceuticals shares at a glance

Information last updated 2021-10-23.
Latest market close$97.23
52-week range$76.34 - $186.82
50-day moving average $104.25
200-day moving average $113.48
Wall St. target price$226.44
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.71

Buy Reata Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Reata Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Reata Pharmaceuticals price performance over time

Historical closes compared with the close of $97.23 from 2021-10-22

1 week (2021-10-15) -1.23%
1 month (2021-09-24) -11.42%
3 months (2021-07-23) -24.92%
6 months (2021-04-23) 9.98%
1 year (2020-10-23) -17.10%
2 years (2019-10-24) -47.62%
3 years (2018-10-24) 74.06%
5 years (2016-10-24) 287.52%

Reata Pharmaceuticals financials

Revenue TTM $7.8 million
Gross profit TTM $-150,061,000
Return on assets TTM -19.53%
Return on equity TTM -99.51%
Profit margin 0%
Book value $8.63
Market capitalisation $3.5 billion

TTM: trailing 12 months

Shorting Reata Pharmaceuticals shares

There are currently 3.9 million Reata Pharmaceuticals shares held short by investors – that's known as Reata Pharmaceuticals's "short interest". This figure is 0.1% down from 3.9 million last month.

There are a few different ways that this level of interest in shorting Reata Pharmaceuticals shares can be evaluated.

Reata Pharmaceuticals's "short interest ratio" (SIR)

Reata Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reata Pharmaceuticals shares currently shorted divided by the average quantity of Reata Pharmaceuticals shares traded daily (recently around 169688.4164859). Reata Pharmaceuticals's SIR currently stands at 23.05. In other words for every 100,000 Reata Pharmaceuticals shares traded daily on the market, roughly 23050 shares are currently held short.

However Reata Pharmaceuticals's short interest can also be evaluated against the total number of Reata Pharmaceuticals shares, or, against the total number of tradable Reata Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reata Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Reata Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1948% of the tradable shares (for every 100,000 tradable Reata Pharmaceuticals shares, roughly 195 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Reata Pharmaceuticals.

Find out more about how you can short Reata Pharmaceuticals stock.

Reata Pharmaceuticals share dividends

We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.

Reata Pharmaceuticals share price volatility

Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $76.34 up to $186.817. A popular way to gauge a stock's volatility is its "beta".

RETA.US volatility(beta: 1.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.5958. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Reata Pharmaceuticals overview

Reata Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd.

Frequently asked questions

What percentage of Reata Pharmaceuticals is owned by insiders or institutions?
Currently 4.904% of Reata Pharmaceuticals shares are held by insiders and 85.517% by institutions.
How many people work for Reata Pharmaceuticals?
Latest data suggests 261 work at Reata Pharmaceuticals.
When does the fiscal year end for Reata Pharmaceuticals?
Reata Pharmaceuticals's fiscal year ends in December.
Where is Reata Pharmaceuticals based?
Reata Pharmaceuticals's address is: 5320 Legacy Drive, Plano, TX, United States, 75024
What is Reata Pharmaceuticals's ISIN number?
Reata Pharmaceuticals's international securities identification number is: US75615P1030
What is Reata Pharmaceuticals's CUSIP number?
Reata Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75615P103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site